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Abstract: Multidrug resistance (MDR) presents a serious challenge to the efficiency of cancer
treatment, and may be associated with the overexpression of drug efflux pumps. P-glycoprotein
(P-gp) is a drug efflux pump often found overexpressed in cases of acquired MDR. Nevertheless,
there are no P-gp inhibitors being used in the current clinical practice, due to toxicity problems,
drug interactions, or pharmacokinetic issues. Therefore, it is important to identify novel inhibitors
of P-gp activity or expression. Curcumin is a secondary metabolite isolated from the turmeric of
Curcuma longa L. which has been associated with several biological activities, particularly P-gp
modulatory activity (by inhibiting both P-gp function and expression). However, curcumin shows
extensive metabolism and instability, which has justified the recent and intensive search for analogs
of curcumin that maintain the P-gp modulatory activity but have enhanced stability. This review
summarizes and compares the effects of curcumin and several curcumin analogs on P-glycoprotein
function and expression, emphasizing the potential of these molecules for the possible development
of safe and effective inhibitors of P-gp to overcome MDR in human cancer.
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1. P-Glycoprotein as a Major Cause of Cancer Multidrug Resistance
Cancer cells may have inherent resistance or may develop resistance to antitumor drugs. In some
cases, cells are cross-resistant to several unrelated (structurally and mechanistically different) drugs,
a phenomenon known as multidrug resistance (MDR) [1,2].
Overexpression of P-glycoprotein (P-gp) is one of the main mechanisms involved in the
development of MDR [1,2]. P-gp (encoded by the MDR1 gene, also referred to as ABCB1) is a
drug-efflux pump from the ATP-binding cassette (ABC) transporters family, which efficiently removes
cytotoxic drugs from the intracellular environment through an ATP-dependent mechanism [3]. This
glycoprotein is composed of two highly hydrophobic integral membrane domains and two hydrophilic
nucleotide-binding domains (Figure 1) [4].
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Figure 1. Schematic representation of P-glycoprotein (P-gp) structure with two halves, each with a 
transmembrane domain (TMD1 and TMD2) and a nucleotide-binding domain (NBD1 and NBD2) 
(adapted from [5]). The transmembrane domains (TMDs)—composed of six membrane α-helices 
(TM1–TM6 and TM7–TM12)—contain the drug binding sites and define the translocation pathway 
across the membrane; the two cytoplasmic nucleotide-binding domains (NBDs) couple the energy 
associated with ATP binding and hydrolysis, which is necessary for drug transport [6]. 
Different studies have shown that by inhibiting P-gp, it is possible to counteract some cases of 
MDR in cancer [7]. There are many known MDR modulators belonging to several chemical classes, 
including calcium channel blockers, indole alkaloids, cyclosporines and calmodulin inhibitors [8]. 
However, the described modulators presented toxicity problems associated with the need for the use 
of very high doses in order to produce the required results [9]. To minimize these risks, new analogs 
of these compounds are being tested and developed, with the goal of finding potent MDR 
modulators with less toxicity problems [10]. 
Some of the most effective cancer treatments to date are derived from natural products, such as 
taxol [11]. Indeed, natural products and their synthetic derivatives comprise more than half of the 
approved anticancer drug candidates developed in the last decades [12]. Research on natural dietary 
phytochemicals from foods, herbs, and dietary supplements is increasing, due to the low expected 
toxicity. 
The search for P-gp inhibitors has uncovered several natural compounds with this activity, such 
as flavonoids, quercetin, morin, catechins, capsaicin, and curcumin [13–15]. In this review, studies 
on the effects of curcumin and curcumin analogs on P-gp expression and activity are summarized, 
with the aim of highlighting the potential of these molecules for the possible development of safe 
and effective inhibitors of P-gp to overcome MDR in human cancer. 
2. Curcumin as a Natural Product that Inhibits P-gp 
Curcumin (Figure 2) is a phytochemical obtained from the dried rhizomes of Curcuma longa L. 
(turmeric), which has been used over the last centuries as a food additive, in cosmetics, and as a form 
of traditional herbal medicine [16]. It has a wide range of pharmacological activities, and presents 
low levels of toxicity. 
Several studies have demonstrated a beneficial effect of curcumin in Alzheimer disease [17], 
and also in cases of high cholesterol through the inhibition of the intestinal absorption of cholesterol, 
consequently reducing its blood levels [18]. Curcumin was also described as an anti-HIV [19] and 
antibacterial agent [20]. Additionally, curcumin presents strong antioxidant, anti-inflammatory, and 
antiangiogenic properties, and was also described as having wound healing and anticancer effects 
[16,21]. 
Figure 1. Schematic representation of P-glycoprotein (P-gp) structure with two halves, each with a
transmembrane domain (TMD1 and TMD2) and a nucleotide-binding domain (NBD1 and NBD2)
(adapted from [5]). The transmembrane domains (TMDs)—composed of six membrane α-helices
(TM1–TM6 and TM7–TM12)—contain the drug binding sites and define the translocation pathway
across the membrane; the two cytoplasmic nucleotide-binding domains (NBDs) couple the energy
associated with ATP binding and hydrolysis, which is necessary for drug transport [6].
Different studies have shown that by inhibiting P-gp, it is possible to counteract some cases of
MDR in cancer [7]. There are many known MDR modulators belonging to several chemical classes,
including calcium channel blockers, indole alkaloids, cyclosporines and calmodulin inhibitors [8].
However, the described modulators presented toxicity problems associated with the need for the use
of very high doses in order to produce the required results [9]. To minimize these risks, new analogs of
these compounds are being tested and developed, with the goal of finding potent MDR modulators
with less toxicity problems [10].
Some of the most effective cancer treatments to date are derived from natural products, such
as taxol [11]. Indeed, natural products and their synthetic derivatives comprise more than half of
the approved anticancer drug candidates developed in the last decades [12]. Research on natural
dietary phytochemicals from foods, herbs, and dietary supplements is increasing, due to the low
expected toxicity.
The search for P-gp inhibitors has uncovered several natural compounds with this activity, such
as flavonoids, quercetin, morin, catechins, capsaicin, and curcumin [13–15]. In this review, studies
on the effects of curcumin and curcumin analogs on P-gp expression and activity are summarized,
with the aim of highlighting the potential of these molecules for the possible development of safe and
effective inhibitors of P-gp to overcome MDR in human cancer.
2. Curcumin as a Natural Product that Inhibits P-gp
Curcumin (Figure 2) is a phytochemical obtained from the dried rhizomes of Curcuma longa L.
(turmeric), which has been used over the last centuries as a food additive, in cosmetics, and as a form
of traditional herbal medicine [16]. It has a wide range of pharmacological activities, and presents low
levels of toxicity.
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Figure 2. Main curcuminoids isolated from turmeric of Curcuma longa L. 
Curcumin inhibits the growth of a wide variety of tumor cells, including gastric cancer [22], 
colon carcinoma [23], and breast cancer cells [24]. Additionally, over the years, extensive clinical 
trials have addressed curcumin’s capacity to treat patients with several types of cancer, such as 
colorectal cancer [25], pancreatic cancer [26], and prostate cancer [27]. Nevertheless, none of these 
clinical trials have reached phase III. Curcumin has been described as inhibiting the phosphorylation 
of protein kinase B (AKT )and AKT-related gene products, thereby presenting antitumor effects [28]. 
In addition, curcumin has been shown to downregulate AKT kinase signaling, inhibiting 
proliferation and inducing apoptosis in T-cell leukemia cell lines [29]. Interestingly, curcumin has 
also been described to be capable of suppressing P-gp expression and function, therefore reversing 
the MDR phenotype [30–32]. 
2.1. Curcumin as Modulator of P-Glycoprotein Function 
Curcumin was described as having a role in reversing MDR through the modulation of P-gp. 
Specifically, curcumin has been described as an inhibitor of the function of P-gp in several in vitro 
and in vivo models [21,33]. 
Several studies revealed that the role of curcumin in the modulation of MDR occurred through 
its interaction with P-gp. In 2002, Anuchapreeda and collaborators [34] demonstrated that curcumin 
reduced P-gp-mediated drug-efflux in MDR cervical carcinoma cells in a dose-dependent manner. 
The authors also performed biochemical studies showing the direct interaction between P-gp and 
curcumin [34]. Two years later, the same group [35] purified the three major curcuminoids from the 
previously-used curcumin mixture [34] (curcumin, demethoxycurcumin, and 
bisdemethoxycurcumin, Figure 2) and analyzed the effect of the three curcuminoids on the 
modulation of P-gp function in the same MDR human cervical carcinoma cell line [35]. The authors 
suggested that these three curcuminoids are not substrates of P-gp, since they presented similar IC50 
values for cytotoxicity between the MDR and the drug-sensitive cell lines used in the study [35]. In 
addition, they observed that curcumin was the most effective MDR modulator among the three 
curcuminoids, and could possibly be used in combination with conventional chemotherapy to 
reverse MDR in cancer [35]. 
Curcumin was also demonstrated to reverse MDR in a different model—a gastric carcinoma 
MDR cell line—possibly through a decrease in P-gp function which was observed in the treated cells 
[36]. In addition, two different MDR human cancer cell models (cervical and breast carcinoma MDR 
cell lines) that were treated with the three major curcuminoids (Figure 2) presented inhibition of 
P-gp function, which significantly increased the intracellular accumulation of rhodamine in a 
dose-dependent manner [37]. Additionally, the interaction of one of curcumin’s metabolites, 
tetrahydrocurcumin, with the P-gp molecule was clearly indicated by an ATPase assay and by photo 
affinity labeling of P-gp [37]. 
The above-mentioned studies were performed in order to study the capacity of curcumin to 
revert MDR. However, curcumin was also shown to have an effect in preventing the induction of 
MDR [38]. This was observed in a chronic myeloid leukemia cell line that was pre-treated with 
curcumin before being exposed for 24 h to doxorubicin with the purpose of selecting for a more 
resistant cell line (with overexpression of P-gp). These cells presented an increase in the intracellular 
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Several studies have demonstrated a beneficial effect of curcumin in Alzheimer disease [17],
and also in cases of high cholesterol through the inhibition of the intestinal absorption of cholesterol,
consequently reducing its blood levels [18]. Curcumin was also described as an anti-HIV [19] and
antibacterial agent [20]. Additionally, curcumin presents strong antioxidant, anti-inflammatory,
and antiangiogenic properties, and was also described as having wound healing and anticancer
effects [16,21].
Curcumin inhibits the growth of a wide variety of tumor cells, including gastric cancer [22],
colon carcinoma [23], and breast cancer cells [24]. Additionally, over the years, extensive clinical trials
have addressed curcumin’s capacity to treat patients with several types of cancer, such as colorectal
cancer [25], pancreatic cancer [26], and prostate cancer [27]. Nevertheless, none of these clinical trials
have reached phase III. Curcumin has been described as inhibiting the phosphorylation of protein
kinase B (AKT )and AKT-related gene products, thereby presenting antitumor effects [28]. In addition,
curcumin has been shown to downregulate AKT kinase signaling, inhibiting proliferation and inducing
apoptosis in T-cell leukemia cell lines [29]. Interestingly, curcumin has also been described to be capable
of suppressing P-gp expression and function, therefore reversing the MDR phenotype [30–32].
2.1. Curcumi as Modulator of P-Glycoprotein Functio
Curcumin was described as having a role in reversing MDR through the modulation of P-gp.
Specifically, curcumin has been described as an inhibitor of the function of P-gp in several in vitro and
in vivo models [21,33].
Several studies revealed that the role of curcumin in the modulation of MDR occurred through
its interaction with P-gp. In 2002, Anuchapreeda and collaborators [34] demonstrated that curcumin
reduced P-gp-mediated drug-efflux in MDR cervical carcinoma cells in a dose-dependent manner.
The authors also performed biochemical studies showing the direct interaction between P-gp and
curcumin [34]. Two years later, the same group [35] purified the three major curcuminoids from the
previously-used curcumin mixture [34] (curcumin, demethoxycurcumin, and bisdemethoxycurcumin,
Figure 2) and analyzed the effect of the three curcuminoids on the modulation of P-gp function
in the same MDR human cervical carcinoma cell line [35]. The authors suggested that these three
curcuminoids are not substrates of P-gp, since they presented similar IC50 values for cytotoxicity
between the MDR and the drug-sensitive cell lines used in the study [35]. In addition, they observed
that curcumin was the most effective MDR modulator among the three curcuminoids, and could
possibly be used in combination with conventional chemotherapy to reverse MDR in cancer [35].
Curcumin was also demonstrated to reverse MDR in a different model—a gastric carcinoma
MDR cell line—possibly through a decrease in P-gp function which was observed in the treated
cells [36]. In addition, two different MDR human cancer cell models (cervical and breast carcinoma
MDR cell lines) that were treated with the three major curcuminoids (Figure 2) presented inhibition
of P-gp function, which significantly increased the intracellular accumulation of rhodamine in
a dose-dependent manner [37]. Additionally, the interaction of one of curcumin’s metabolites,
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tetrahydrocurcumin, with the P-gp molecule was clearly indicated by an ATPase assay and by photo
affinity labeling of P-gp [37].
The above-mentioned studies were performed in order to study the capacity of curcumin to revert
MDR. However, curcumin was also shown to have an effect in preventing the induction of MDR [38].
This was observed in a chronic myeloid leukemia cell line that was pre-treated with curcumin before
being exposed for 24 h to doxorubicin with the purpose of selecting for a more resistant cell line (with
overexpression of P-gp). These cells presented an increase in the intracellular rh123 accumulation
levels, and an increase in the sensitivity towards doxorubicin (almost comparable to cells that were not
exposed to doxorubicin), whereas the cells that were not pretreated with curcumin (but exposed to
doxorubicin) presented a decrease in the intracellular rh123 accumulation levels and became more
resistant to doxorubicin [38].
The previously mentioned studies reveal the potential of curcumin as an inhibitor of P-gp function.
This particular activity of curcumin may contribute in the future to change clinical practices in cancer
treatment, since the inhibition of P-gp function may help to counteract the MDR phenotype in some
cancer patients.
2.2. Curcumin as Modulator of P-Glycoprotein Expression
Curcumin has been described to not only inhibit the function of P-gp, but also the expression
of P-gp at the protein and at the mRNA level. This role of curcumin as inhibitor of the expression
of P-gp was originally described in 2002 [34], in a work in which it was shown that treatment of
MDR cervical carcinoma cells caused a decrease in the protein and mRNA levels of P-gp [34]. Later
on, the same authors isolated three more important natural curcuminoids from turmeric (Figure 2,
curcumin, demethoxycurcumin, and bisdemethoxycurcumin) and compared them for their ability to
modulate P-gp expression in the same model (a MDR human cervical carcinoma cell line) [39]. They
have demonstrated that bisdemethoxycurcumin was the most active of the curcuminoids present in
turmeric regarding the inhibition of the P-gp expression. In addition, treatment of the MDR cells
with curcumin increased their sensitivity to vinblastine, which was consistent with a decrease in P-gp
expression [39].
The effect of curcumin in P-gp expression was also demonstrated in other MDR cancer cell
models, such as in a human MDR gastric cancer cell line [36], a human MDR colon cancer cell line [40],
and a mouse MDR leukemia cell line [31], in which it was described that the inhibitory effect of
curcumin in the expression of P-gp ultimately led to MDR modulation and cellular sensitization to
common drugs. From a mechanistic point of view, it was proposed that curcumin can contribute
to counteract the MDR phenotype, probably by suppression of P-gp expression via inhibition of
the Phosphatidylinositol-4,5-bisphosphate 3-kinase/AKt/factor nuclear kappa B (PI3K/Akt/NF-kB)
signaling pathway [31].
The role of curcumin in preventing MDR by decreasing P-gp expression in a chronic myeloid
leukemia model was also shown [38]. In addition, it was found that all the three curcuminoids
(curcumin, demethoxycurcumin, and bisdemethoxycurcumin, Figure 2) were capable of preventing
MDR induced by doxorubicin in that model (chronic myeloid leukemia). However, the preventive
effect of each curcuminoid was different, with demethoxycurcumin being the most active of the
curcuminoids for the prevention of MDR1 mRNA and P-gp overexpression [41].
Finally, it was demonstrated that both the chemotherapeutic and chemosensitizing effects of
curcuminoids (by downregulation of P-gp expression) in colon cancer cells were mediated through
modulation of a microRNA (miR-27a-ZBTB10-Sp-axis) [42].
Although these works have demonstrated that curcumin is an effective inhibitor of P-gp
expression in vitro, animal experimentation was further required to determine if curcumin had
potential as an effective and safe chemosensitizer. Curcumin was shown to have the capacity to
inhibit the expression of P-gp in xenografts of human colon cancer cells in mice. Indeed, curcumin
treatment significantly reduced the expression of the MDR1 gene and of P-gp protein in the xenografts
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of mice, when compared to the control group [40]. These results suggested that curcumin could
partially reverse the MDR phenotype. Additionally, curcumin inhibited xenograft growth [40]. The
P-gp inhibitory activity of curcumin was also demonstrated in an in vivo model of colon cancer, by a
novel method—the in situ cancerous colonic single pass perfusion method in rats [32].
The above-mentioned role of curcumin as inhibitor of P-gp expression in different in vitro and
in vivo cancer models further strengthens the need for more clinical trials to study the clinical feasibility
of using curcumin to counteract the MDR phenotype in cancer patients.
3. Strategies for Overcoming the Limitations of Curcumin
The previously mentioned studies suggested that curcumin could become a promising lead
compound for overcoming MDR in cancer. However, this compound is very unstable, and has low
bioavailability in vivo [21]. Indeed, curcumin is highly hydrophobic, which prevents its absorption
across the gut, therefore having a rapid metabolism and a limited tissue distribution [43]. In summary,
the instability of the molecule and its poor pharmacokinetics profile are major drawbacks for its
possible clinical use. This became evident in a Phase I clinical trial, during which very high oral doses
of curcumin (8–12 g/daily) resulted in peak plasma concentrations in the nanomolar range only [44,45].
Therefore, two strategies have been employed in order to overcome this problem: the incorporation of
curcumin into pharmaceutical formulations to improve its delivery, and the design and synthesis of
analogs of curcumin aiming to obtain better stability and bioavailability.
3.1. Improving the Intracellular Delivery of Curcumin
The delivery of curcumin may be improved with the help of nanotechnology. Indeed, it has
been reported that a more pronounced downregulation of P-gp expression was observed when
curcumin was delivered in nanoemulsion formulations (heterogeneous mixtures of oil in water, where
the oil droplets have a nanometer size, which allow the solubilization of curcumin, since it is a
hydrophobic compound) when compared to curcumin alone [46]. In this study, human MDR ovarian
adenocarcinoma cells were treated with paclitaxel and curcumin, both encapsulated in nanoemulsion
formulations. The results obtained showed that the encapsulated drugs were effectively delivered,
and that curcumin downregulated P-gp expression in a more effective way than when administered
without being encapsulated in nanoemulsions [46]. Another study used lipid nanoparticles loaded
with doxorubicin and curcumin to treat mice with induced hepatocellular carcinoma. This combined
formulation increased cellular cytotoxicity and decreased P-gp expression [47].
It is also possible to use polymers to improve the delivery of curcumin. Indeed, in a recent
study, MDR breast cancer cells were treated with a biotin–Polyethylene glycol (PEG)–PCDA
(poly(curcumin-dithio dipropionic acid) polymeric nanocarrier loaded with paclitaxel, magnetic
nanoparticles, and quantum dots [48]. The nanoparticles presented high uptake by tumor cells,
and curcumin (cleaved product of PCDA) downregulated the expression of P-gp, allowing an
increase in paclitaxel accumulation within the target cancer cells, thereby enhancing the therapeutic
efficacy against the MDR cells [48]. Furthermore, it was shown that curcumin encapsulated
in chitosan–polybutyl cyanoacrylate nanoparticles decreased the expression levels of P-gp in
MDR cells when compared to control treatments with curcumin alone [49]. In this study,
MCF-7-doxorubicin-resistant cells were treated with several preparations of chitosan–polybutyl
cyanoacrylate nanoparticles containing curcumin, doxorubicin, or both, and the cellular P-gp
expression levels and the cytotoxic effects were then assessed. The results showed a significant
improvement in the cytotoxic effect and in the P-gp inhibitory effect when using encapsulated
curcumin [49]. Moreover, polylactic-co-glycolic acid nanoparticles containing curcumin were described
in another study as having a higher cellular uptake and cytotoxic effect in cervical cancer cells, when
compared to curcumin alone [50]. Furthermore, in a subsequent study, these authors conjugated the
same nanoparticles (loaded with curcumin) with an anti-P-gp antibody in order to obtain a more
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targeted therapy [51]. These new nanoparticles presented a more pronounced cytotoxic effect against
an MDR cervical cancer model than the nanoparticles without the P-gp antibody [51].
The encapsulation of curcumin (alone or in combination with another drug) within micelles has
also been described [52–55]. The improved effects of this type of formulation could be attributed to the
solubilization of the hydrophobic curcumin in the micelle core, together with the P-gp inhibitory effect
of curcumin. For instance, a preparation of mixed micelles (polymeric micelles and surfactant micelles)
loaded with curcumin caused a significant improvement in the cytotoxic activity on human MDR
lung cancer cells and in their oral bioavailability, when compared to curcumin alone [52]. In addition,
a Poloxamer 407 and a D-alpha-tocopheryl polyethylene glycol 1000 succinate mixed micelle with
encapsulated curcumin, were developed and tested in MDR ovarian cancer cells [53]. The micelles
containing curcumin were capable of inducing an increase in the intracellular uptake of curcumin,
as well as an increase in the cytotoxic effect (when compared to curcumin alone) [53]. Another
micelle preparation (pegylated polymeric micelle) was developed to co-encapsulate doxorubicin
and curcumin [54]. The co-delivered micelles exhibited excellent cytotoxicity, reverted the MDR
phenotype, and promoted an increase in the cellular uptake of doxorubicin, which induced apoptosis
in MCF7/Adr MDR cells [54]. Finally, in another work, amphiphilic polymeric micelles were prepared,
also in order to encapsulate doxorubicin and curcumin [55]. MCF7/Adr MDR cells were treated with
those micelles, and the cellular uptake of doxorubicin, the cellular drug efflux rate, the downregulation
of P-gp expression, and the inhibition of ATP activity were assessed. Results showed a higher cellular
uptake and lower efflux rate of doxorubicin, and a stronger effect on the downregulation of P-gp and
inhibition of ATP activity in cells treated with the co-encapsulated micelles, when compared to control
treatments (curcumin and/or doxorubicin alone). Additionally, those micelles presented increased
tumor accumulation and stronger inhibitory effect on tumor growth in a xenograft model of the same
MDR cells, when compared to other drug formulations [55].
All of the above-mentioned strategies using pharmaceutical formulations to improve curcumin
delivery proved to be important approaches to overcome the low bioavailability of curcumin.
3.2. Curcumin Derivatives and Analogs as Inhibitors of P-gp
Over the past few years, several curcumin derivatives/analogs have been synthesized with the
objective of obtaining molecules more stable and bioavailable than curcumin, while not losing their
biological activity (Table 1).
Table 1. Reported curcumin derivatives/analogs with P-gp modulatory effect.
Compounds MDR Cancer Model Inhibitors ofP-gp Function
Inhibitors of
P-gp Expression References
Unsymmetrical
curcumin mimics with
various amide moieties
MDR cervical
adenocarcinoma X [56]
Heterocyclic
cyclohexanone
monocarbonyl analogs
of curcumin
Human embryonic
kidney cells and canine
kidney cells transfected
with wild-type P-gp
X [57]
Chloro and
asymmetrical series of
synthetic curcumin
derivatives
MDR acute
lymphoblastic leukemia X [58]
Diketone and
cyclohexanone
curcumin analogs
MDR chronic myeloid
leukemia X X [59]
MDR: multidrug resistant.
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Several authors have attempted to understand the MDR modulatory effect of curcumin and the
disadvantages that curcumin presents in terms of pharmacokinetics profile from a chemical perspective.
They have attempted to synthesize better compounds; i.e., maintaining the MDR modulatory effect
while improving the stability and availability of curcumin.
Given the importance of curcumin in cancer treatment, several curcumin derivatives/analogs
have been synthesized and studied over the past few years; however, only a few candidates have
been studied as MDR modulators (by inhibiting P-gp function and/or P-gp expression). For instance,
12 unsymmetrical curcuminoids with various amide groups were synthesized and tested for MDR
reversal activity. These compounds were tested in MDR cervical adenocarcinoma P-gp overexpressing
cells, together with vincristine and paclitaxel (in comparison with verapamil as a positive control), in
order to access their MDR modulatory capacity. Three of the compounds presented a potent MDR
reversal activity by inhibiting the drug efflux function of P-gp, while the others were only moderately
potent [56]. This work also showed—from the preliminary structure–activity study—that only half of
the curcumin symmetrical structure is a promising lead structure for a MDR reversal agent, particularly
one or two chloride groups at the meta- or para- position on benzamide [56].
Moreover, monocarbonyl analogs of curcumin have been described to be more stable than
curcumin, since they do not have the unstable β-diketone moiety of curcumin [60]. Nonetheless, most
studies with monocarbonyl analogs have focused on the anticancer, antibacterial, anti-inflammatory,
and antioxidant effects, and very little is known about their ability to inhibit ABC transporters such as
P-gp. Indeed, 23 heterocyclic cyclohexanone monocarbonyl analogs of curcumin were synthesized,
and were initially investigated for their possible inhibitory effects on the function of several ABC
transporters, including P-gp (using flow cytometry and resistance reversal assays) [57]. Besides
being more stable than curcumin, many of these compounds inhibited P-gp function, most of them
being more potent than curcumin itself. Moreover, some of these analogs showed potent anticancer
activity [57], which raised the possibility of using them as antitumor dual agents (similarly to the
above described curcumin effect).
Additionally, the cytotoxic and P-gp inhibitory activities of 19 chloro and asymmetrical series of
synthetic curcumin derivatives were studied in a MDR acute lymphoblastic leukemia model, and in its
drug-sensitive counterpart cell line [58]. Four moieties have been explored for structural modification
of curcumin: the aryl side chain, the diketo group, the double bond, and the active methylene groups.
Based on these hypotheses, 19 new compounds were synthesized, and the biological results obtained
showed that MDR cells exhibited cross-resistance to 10 compounds, collateral sensitivity to three
compounds, and regular sensitivity to the other six compounds. Some of them caused a significant
increase in doxorubicin uptake rates (an effect that was better than that observed with verapamil),
indicating a remarkable inhibition of P-gp function (since doxorubicin is a P-gp substrate) [58].
However, in terms of ATPase activity, results showed that the novel compounds did not induce
basal (and verapamil-stimulated) P-gp-ATPase activity in a comparable manner to verapamil [58].
Finally, five diketone and four cyclohexanone curcumin analogs were synthesized, and
the modified substitution moieties were on the aromatic ring, while four of the cyclohexanone
analogs were investigated by replacing the di-ketone with cyclohexanone having modifications
on the functional groups on the aromatic ring. These compounds were analyzed regarding
the intracellular accumulation of P-gp substrates (such as rhodamine 123 and doxorubicin) in
a MDR chronic myeloid leukemia model, in order to evaluate their effect as inhibitors of P-gp
function. Two of these compounds (1,7-bis-(3,4-dimethoxy-phenyl)-hepta-1,6-diene-3,5-dione and
2,6-bis-(3,4-dimethoxy-benzylidene)-cyclo-hexanone) caused a strong inhibitory effect of P-gp
function [59], which suggests that these analogs may be strong MDR modulators.
From the above-mentioned published studies, only one study investigated the inhibitory activity
of the analogs in terms of P-gp expression [59]. From the studied diketone and four cyclohexanone
curcumin analogs mentioned above, three of them showed a strong effect as inhibitors of P-gp
expression. Interestingly, one of the analogs (2,6-bis-(3,4-dimethoxy-benzylidene)-cyclo-hexanone)
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caused simultaneous inhibition of the expression and function of P-gp [59]. This compound might be a
very good candidate for an MDR modulator, since it has dual inhibitory effects (on both P-gp function
and expression), increased the sensitivity of the MDR cells to paclitaxel, and also has better stability
than curcumin itself.
These studies provide a basis for further systematic activity improvement of synthetic curcumin
derivatives and analogs. Curcumin exerts MDR reversal activity, and therefore chemical modifications
of curcumin may improve its biological activities. Therefore, curcumin derivatives and analogs should
be investigated in more detail, in order to address the limitations of curcumin and to improve its
biological activities—in particular the P-gp modulatory effect, which is still not very thoroughly
explored. Moreover, it will be important to improve the dual activity of curcumin derivatives or
analogs, since stable concomitant inhibitors of tumor growth and P-gp activity are promising leading
compounds to proceed to clinical studies in order to improve treatment of MDR cancer patients.
4. Future Perspectives
It is believed that the level of P-gp in cell lines is much higher than that in human tissues [61],
which means that lower concentrations of P-gp modulators should be effective inhibitors of P-gp
in vivo, when compared to in vitro studies. Therefore, even though curcumin and derivatives are
considered to be non-toxic, a low therapeutic dose could be favorable in future in vivo studies.
Future studies should also consider the synergistic effects of curcumin with other compounds, on
P-gp transporter function and expression. Combinatorial studies with several natural compounds or
with conventional anticancer drugs could be carried out in order to identify potential synergistic or
additive effects.
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